--- title: "Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/284553992.md" datetime: "2026-04-29T11:04:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284553992.md) - [en](https://longbridge.com/en/news/284553992.md) - [zh-HK](https://longbridge.com/zh-HK/news/284553992.md) --- # Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B Revenue: As of FY2026 Q1, the actual value is USD 1.244 B, beating the estimate of USD 1.216 B. EPS: As of FY2026 Q1, the actual value is USD -0.2, missing the estimate of USD -0.1475. EBIT: As of FY2026 Q1, the actual value is USD 126 M. #### Total Revenue Bausch + Lomb Corporation reported total revenue of $1.244 billion for the first quarter of 2026, an increase of $107 million, or 9%, compared to $1.137 billion in the first quarter of 2025. On a constant currency basis, revenue grew approximately 6% compared to the first quarter of 2025 . #### Segment Revenue - **Vision Care**: Revenue was $711 million for the first quarter of 2026, up $55 million or 8% from $656 million in the first quarter of 2025. Excluding foreign exchange impacts, segment revenue increased by approximately 5% on a constant currency basis, driven by sales from over-the-counter dry eye products, LUMIFY®, and SiHy Daily lenses . - **Surgical**: Revenue reached $228 million in the first quarter of 2026, an increase of $14 million or 7% from $214 million in the first quarter of 2025. On a constant currency basis, segment revenue increased by approximately 1%, primarily due to growth in premium IOLs and consumables . - **Pharmaceuticals**: Revenue was $305 million for the first quarter of 2026, marking an increase of $38 million or 14% from $267 million in the first quarter of 2025. On a constant currency basis, segment revenue grew by approximately 12%, largely driven by increased sales of MIEBO® (+33%) and XIIDRA® (+30%), and growth in International Pharmaceuticals . #### Operating Income Operating income for the first quarter of 2026 was $33 million, a favorable change of $116 million compared to an operating loss of - $83 million in the first quarter of 2025. This change was attributed to revenue performance and operating efficiencies . #### Net Loss Attributable to Bausch + Lomb Corporation Net loss attributable to Bausch + Lomb Corporation was - $71 million for the first quarter of 2026, a favorable change of $141 million from - $212 million in the first quarter of 2025. This improvement was primarily due to increased operating results and a favorable change in the provision for income taxes . #### Adjusted Net Income (non-GAAP) Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) was $19 million in the first quarter of 2026, a favorable change of $73 million from an adjusted net loss of - $54 million in the first quarter of 2025 . #### Cash Flow from Operations Cash flow from operations for the first quarter of 2026 was $32 million, a favorable change of $57 million compared to cash flow used in operations of - $25 million in the first quarter of 2025. The positive impact was linked to operating results . #### Adjusted EBITDA (non-GAAP) Adjusted EBITDA (non-GAAP) was $189 million for the first quarter of 2026, an increase of $91 million from $98 million in the first quarter of 2025. Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) was $200 million for the first quarter of 2026, an increase of $74 million from $126 million in the first quarter of 2025. These increases were driven by revenue performance and operating efficiencies . #### Balance Sheet Highlights As of March 31, 2026, Bausch + Lomb Corporation held $279 million in cash, cash equivalents, and restricted cash . #### 2026 Financial Outlook Bausch + Lomb Corporation raised its full-year 2026 guidance for both revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) . The company now expects full-year revenue to be between $5.420 billion and $5.520 billion, with constant currency growth projected at 5.3% to 7.2% . Full-year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) is anticipated to range from $1.010 billion to $1.060 billion . ### Related Stocks - [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md) ## Related News & Research - [Bausch + Lomb Q1 revenue rises 9%, beats estimates; lifts 2026 outlook](https://longbridge.com/en/news/284554423.md) - [Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday](https://longbridge.com/en/news/283635818.md) - [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md) - [Bally’s Corporation Reports First Quarter 2026 Results | BALY Stock News](https://longbridge.com/en/news/286814213.md) - [Bausch Health Announces 2026 Annual Meeting of Shareholder Results | BHC Stock News](https://longbridge.com/en/news/286961143.md)